Following is a cumulative list of Hoosier Cancer Research Network publications in breast cancer.

Manuscripts and Journal Articles

• Bryan P. Schneider,MD; Guanglong, Jiang,MS; Tarah J. Ballinger, MD; Fei Shen, MD; Christopher Chitambar, MD; Rita Nanda, MD; Carla Falkson, MBBch, PhD; Filipa C. Lynce , MD; Christopher Gallagher , MD; Claudine Isaacs , MD; Marcelo Blaya, MD; Elisavet Paplomata, MD; Radhika Walling, MD; Karen Daily , DO; Reshma Mahtani , DO; Michael A. Thompson , MD, PhD; Robert Graham, MD; Maureen E. Cooper, BS; Dean C. Pavlick , BS; Lee A. Albacker , PhD; Jeffrey Gregg, MD; Jeffrey P. Solzak , MS, MBA; Yu-Hsiang Chen, PhD; Casey L. Bales , MS; Erica Cantor , MS; Bradley A. Hancock, BS; Nawal Kassem , MD; Paul Helft, MD; Bert O’Neil, MD; Anna Maria V. Storniolo , MD; Sunil Badve , MBBS; Kathy D. Miller, MD; and Milan Radovich , PhD. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician’s Choice for Patients with Residual Triple-Negative Breast Cancer. (BRE12-158) Journal of Clinical Oncology 40, no. 4 (February 01, 2022) 345-355. DOI: 10.1200/JCO.21.01657 See abstract. 
• M Kalra, Y Tong, DR Jones, T Walsh, MA Danso, CX Ma, P Silverman, M King, SS Badve, SM Perkins, KD Miller. Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. (BRE09-146) npj Breast Cancer 7, 29 (2021). https://doi.org/10.1038/s41523-021-00240-w. See abstract.
• M Radovich, G Jiang, BA Hancock, C Chitambar, R Nanda, C Falkson, FC Lynce, C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick, LA Albacker, J Gregg, JP Solzak, Y Chen, CL Bales, E Cantor, F Shen, AMV Storniolo, S Badve, TJ Ballinger, C Chang, Y Zhong, C Savran, KD Miller, BP Schneider. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol. Published online July 09, 2020. doi:10.1001/jamaoncol.2020.2295. See abstract.
• Schneider B, Miller KD, Badve S, O’Neil B, Helft P, Chitambar C, Falkson C, Nanda R, McCormick M, Danso M, Blaya M, Langdon R, Lippman M, Paplomata E, Walling R, Thompson M, Robin E, Aggarwal L, Shalaby I, Canfield V, Adesunloye B, Lee T, Daily K, Ma C, Erban J, Radhakrishnan N, Bruetman D, Graham M, Reddy NA, Lynce FC, Radovich M. BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC). A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-04-01. See abstract.
• Mina L, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Invest New Drugs (2013) 31:1307–1310 DOI 10.1007/s10637-013-9976-1
• IE Krop, KD Miller, RT Zon, S Isakoff, CJ Schneider, M Yu, C Johnson, LG Vaughn, OO Shonukan, GW Sledge Jr. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen: HOG BRE05–97. DOI: 10.1200/jco.2008.26.15_suppl.1004 Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008) 1004-1004. See abstract.
• Catherine P Riley, Xiang Zhang, Harikrishna Nakshatri, Bryan Schneider, Fred E Regnier, Jiri Adamec. Charles Buck. A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples. COE-05 Journal of Translational Medicine 2011 9:80. doi:10.1186/1479-5876-9-80, 27May2011
• Chao C, Studts JL, Abell T, Hadley T, Roetzer L, Dineen S, Lorenz D, YoussefAgha A, McMasters KM. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making: Hoosier Oncology Group BRE02-43. J Clin Oncol. 2003 Dec 1;21(23):4299-305. Epub 2003 Oct 27 PMID: 14581440
• Miller KD, Sisk J, Gize G. Phase II Study of Gemcitabine, Paclitaxel and Trastuzumab in Metastatic Breast Cancer: A Hoosier Oncology Group Study BRE99-1. Breast Cancer Res Treat 2002;76(suppl 1):S113.
• Soule SE, Miller KD, Porcu P, Ansari R, Fata F, McClean JW, Zon R, Sledge GW, Einhorn LH. Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer: Hoosier Oncology Group BRE98-1. Annals of Oncology 13: 1612-1615, 2002.
• Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, Sledge Jr G. Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer: A Hoosier Oncology Group Trial BRE96-1. American Society of Clinical Oncology 17: No. 10 (October),1999:pp3033-3037
• Roth BJ, Sledge GW, Williams SD, Meyer SC, Ansari R, Fisher WB: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) in Metastatic Breast Cancer: A Phase II Trial of the Hoosier Oncology Group. Cancer 68: 248-252, 1991.

Abstracts, Posters, and Presentations

• Vidula N, Nanda R, Miller K, Emens L, Abramson V, Park B, Liu MC, Goga A, Rugo H. Randomized phase II trial of pembrolizumab/carboplatin vs. carboplatin alone for breast cancer with chest wall recurrence: TBCRC044. oster Session, San Antonio Breast Cancer Symposium 2021. See abstract. 
• M Radovich, N Kassem, G Jiang, BA Hancock, BP Schneider. Circulating TP53 mutations in TNBC after neoadjuvant chemotherapy is associated with rapid disease recurrence: Correlative analysis from clinical trial BRE12-158. Spotlight Poster Discussion Session, San Antonio Breast Cancer Symposium 2020. See abstract.
• M Radovich, G Jiang, C Chitambar, R Nanda, C Falkson, FC Lynce, C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick, L Albacker, J Gregg, CL Bales, BA. Hancock, E Cantor, F Shen, AMV Storniolo, S Badve, T Ballinger, KD Miller, BP Schneider. Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158. General Session, San Antonio Breast Cancer Symposium 2019. See abstract.
• Schneider B, Miller KD, Badve S, O’Neil B, Helft P, Chitambar C, Falkson C, Nanda R, McCormick M, Danso M, Blaya M, Langdon R, Lippman M, Paplomata E, Walling R, Thompson M, Robin E, Aggarwal L, Shalaby I, Canfield V, Adesunloye B, Lee T, Daily K, Ma C, Erban J, Radhakrishnan N, Bruetman D, Graham M, Reddy NA, Lynce FC, Radovich M. BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC). Ongoing Clinical Trials Poster, San Antonio Breast Cancer Symposium 2016. See abstract.
• Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 1082). See abstract.
• S. Dwadasi, Y. Tong, T. Walsh, M.A. Danso, C.X. Ma, P.A Silverman, M.C. King, S.M. Perkins, S.S. Badve, K. Miller. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Hoosier Oncology Group BRE09-146. Accepted for poster discussion at the Poster Highlights Session, Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy at the ASCO Annual Meeting May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 1019^). See abstract.
• R Audet, C Shen, S Willis, R Duchnowska, K Adamowicz, J Zok, W Rogowski, MM Litwiniuk, S Debska, M Jaworska, M Foszczynska-Kloda, M Kulma-Kreft, K Zabkowska, J Jassem, S Edgerton, AD Thor, K Miller, GW Sledge, B Leyland-Jones. Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients: COE-05. Accepted as an abstract to the ASCO Annual Meeting, June 1-5, 2012, Chicago IL. J Clin Oncol 30, 2012 (suppl; abstr e21099)
• S. R. Malireddy, S. M. Perkins, S. S. Badve, G. W. Sledge, K. Miller. PARP inhibition after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146. Accepted as a Poster Presentation at the Trials in Progress Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr TPS130). See abstract.
• R. Audet, R. Duchnowska, K. Adamowicz, J. Zok, W. Rogowski, M. Litwiniuk, S. Debska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft, K. Zabkowska, C. Shen, S. Edgerton, K. Vang Nielsen, A. Thor, J. Chang, K. Miller, J. Jassem, G. Sledge, B. Leyland-Jones. Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in breast cancer patients: Hoosier Oncology Group COE-05. Accepted as a Poster Presentation at the General Poster Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 10629)
• B. Leyland-Jones, K. Miller, P. Silverman, C. Shen, C. Williams, T.Breen, G. Sledge. A Phase II Study of Lonafarnib (LF) in Patients with Locally Advanced and Metastatic Breast Cancer (MBC): Hoosier Oncology Group BRE07-126. Accepted as a Poster Presentation at the General Poster Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 598)
• Kathy D. Miller, Judy Sisk, Gary Gize, Sreenivasa Nattam, Rafat Ansari, Jake Vinson and George Sledge. Phase II study of gemcitabine, paclitaxel and trastuzumab in metastatic breast cancer; a Hoosier Oncology Group trial BRE99-1. Presented at the San Antonio Breast Cancer Symposium, December 11-14, 2002.
• Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Sledge Jr G. Randomized Pilot Trial of Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer: A Hoosier Oncology Group Trial BRE96-1 and Walther Cancer Institute, Indianapolis, IN. Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA
• McCaskill-Stevens W, Ansari R, Fisher W, Pennington K, Dobbs C, Gonin R, Schafer S, Loesch D, Sledge G. A Hoosier Oncology Group Phase II Study of Biweekly Cisplatin (C) and Paclitaxel (P) in the Treatment of Metastatic Breast Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial BRE94-1. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.
• Sledge GW, Jr., Stevens W, Sciortino D, Ansari R, Einhorn LH: Carboplatin and WR-2721 as First-Line Chemotherapy for Metastatic Breast Cancer (MBC): A Hoosier Oncology Group Study BRE89-1. Breast Cancer Research and Treatment meeting 1991, San Antonio, TX.
• Roth BJ, Sledge GW, Williams SD, Fisher WB, Meyer SC: Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M VAC) as First Line Chemotherapy in Metastatic Breast Cancer: A Phase II Trial of the Hoosier Oncology Group. Proc Am Soc Clin Oncol 7:3l, l988.